drugset / Trial / NCT03295162

Effects of Melatonin as a Novel Antioxidant and Free Radicals Scavenger in Neonatal Sepsis

NCT03295162

Phase 1/2 Completed 55 enrolled Mohamed Hussein Metwally
RandomizedParallel-groupOpen-labelSupportive care

Summary

Assess the efficacy of melatonin as an adjuvant in the treatment of free radical disease in septic preterms receiving melatonin compared to those on conventional treatment through measuring the level of Malondialdehyde as a marker of oxidative stress and by comparing other clinical and laboratory parameters of sepsis in both groups.

Timeline

Start
2015-11-26
Primary completion
2017-03-01
Completion
2017-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Melatonin Small molecule 10 mg Other

Indications